拉米夫定联合抗乙肝胎盘转移因子治疗慢性乙型肝炎疗效及对T淋巴细胞的影响

Effect of Lamivudine combined with anti-HBV placenta transfer factor combination therapy on patients with chronic hepatitis B and influence on T-cell subset

目的观察拉米夫定联合抗乙肝胎盘转移因子治疗慢性乙型肝炎的疗效及对T淋巴细胞亚群的影响。方法将60例慢性乙型肝炎患者随机分为2组各30例,均予拉米夫定100 mg每日早晨空腹顿服,治疗组同时予抗乙肝胎盘转移因子4 mL肌肉注射,2组疗程均为3个月。检测治疗前及治疗后每个月2组患者的ALT水平及HBeAg、HBV-DNA、T淋巴细胞亚群变化。结果治疗3个月后,治疗组的HBV-DNA阴转率和ALT复常率均显著高于对照组(P<0.05),外周血CD4亚群水平上调,CD4/CD8比值趋于正常,与对照组相比有显著性差异(P<0.05)。结论拉米夫定联合抗乙肝胎盘转移因子治疗慢性乙型肝炎疗效显著。

Objective It is to observe the effect of combined application of Lamivudine and anti-HBV placenta transfer factor on patients with chronic hepatitis B and its influence on T - cell subset. Methods 60 patients were chosen and randomly divided into two groups：the treated group （30 cases） and the control group （30 cases）. Both groups were received Lamivu- dine 100 mg daily for 3 month and treat group were added with anti-HBV placenta transfer factor 4 mg daily. Both the treat-ment courses were 3 months＇treatment. The indexes of ALT, HBeAg, HBV- DNA,T- cell subset were determined and observed before treatment and two months after treatment. Results After 3 months＇ treatment, the negative rate of serum HBVDNA and ALT normalization rate in treated group were both higher than that in control group（ P 〈 0.05）. CD4 T- cell level increased and CD4/CD8 became normal in treated group, and there were significant differences between the two groups （P 〈 0.05）. Conclusions Lamivudine combined with anti-HBV placenta transfer factor has a good curative effect on patients with chronic hepatitis B.